arrow
S

Satoshi Yoshihara

Hyogo Medical University
H指数:32
被引数:3,609

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic factors of second allogeneic hematopoietic stem cell transplantation for relapsed or refractory myelodysplastic syndromes: nationwide registry analysis

复发或难治性骨髓增生异常综合征二次同种异基因造血干细胞移植的预后因素:全国登记研究分析

2026-08-190
PRE
Pre-transplant molecular international prognostic scoring system score reduction is not associated with improved outcomes in myelodysplastic syndromes

移植前分子国际预后评分系统评分降低与骨髓增生异常综合征的预后改善无关

2026-07-270
OAAI
Chromatin landscape and epigenetic heterogeneity of acute myeloid leukaemia

急性髓系白血病的染色质景观和表观遗传异质性

Nature
IF48.5
2026-07-080
OAAI
Retrospective comparison of mesenchymal stromal cells and antithymocyte globulin as second-line therapy for acute graft-versus-host disease

间充质基质细胞与抗胸腺细胞球蛋白作为急性移植物抗宿主病二线治疗的回顾性比较

2026-06-110
OAAI
Comparative outcomes of umbilical cord blood transplantation versus haploidentical transplantation according to post-transplant cyclophosphamide use in adolescent and young adult patients

根据使用环磷酰胺后,脐带血移植与单倍型相合移植在青少年和年轻成年患者中的比较结局

2026-05-290
PRE
Drivers of Temporal Improvement in CAR T-Cell Therapy for Large B-Cell Lymphoma: A Japanese Nationwide Registry Analysis

大B细胞淋巴瘤CAR T细胞疗法的时效性改善驱动因素:一项日本全国注册登记分析

2026-04-250
OAAI
Insights into very elderly multiple myeloma treatment from Kansai Myeloma Forum

从关西骨髓瘤论坛对极高龄多发性骨髓瘤治疗的见解

2025-12-310
PRE
Real-world outcomes of tisagenlecleucel treatment in patients with relapsed or refractory large B-cell lymphomas: A nationwide registry

复发或难治性大B细胞淋巴瘤患者tisagenlecleucel治疗的实际世界结果:一项全国性登记研究

2025-12-240
PRE
Autologous peripheral blood mononuclear cell-loaded injectable cell scaffold (ICS-001) for revolutionising angiogenic therapy: a study protocol for an exploratory clinical trial
2025-10-230
OA
PS13.3: Exploratory physician-initiated clinical trial for innovative angiogenic therapy using injectable cell scaffold (ICS-001) with peripheral blood mononuclear cells for chronic limb threatening ischemia.

PS13.3: 探索性医生发起的临床试验,针对慢性肢体威胁性缺血的创新血管生成疗法,使用注射用细胞支架(ICS-001)与外周血单核细胞。

2025-10-200
PRE
Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC

急性GVHD第28天治疗反应标准的修订:JSTCT与MAGIC的合作研究

2025-07-030
OAAI
Survival outcomes and risk factors of second allogeneic hematopoietic cell transplantation in non-remission status for acute myeloid leukemia

非缓解状态下急性髓系白血病的第二次异基因造血细胞移植的生存结局和危险因素

2025-06-090
PRE
Fludarabine Plus Myeloablative Dose of Busulfan Regimen Was Associated with High Nonrelapse Mortality in Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Lymphoma: A Propensity Score-Matched Comparison Study with Fludarabine Plus High-Dose Melphalan

氟达拉滨联合大剂量白消安方案与异基因造血干细胞移植治疗恶性淋巴瘤的高非复发死亡率相关:一项与氟达拉滨联合高剂量美法仑方案的倾向性评分匹配比较研究

2025-06-010
PRE
Classical and Late-Onset SOS/VOD After Allogeneic HSCT: A Japanese Transplant Registry Analysis

同种异基因造血干细胞移植后的经典型和迟发型SOS/VOD:一项日本移植登记研究

2025-05-190
PRE
CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant

CAR T或NK细胞靶向急性髓系白血病异基因造血干细胞移植后不匹配的HLA-DR分子

2025-03-241
PRE
Allogeneic hematopoietic stem cell transplantation using reduced intensity conditioning regimen for patients with acute myeloid leukemia not in complete remission

减强度预处理方案异基因造血干细胞移植治疗未完全缓解的急性髓系白血病

2025-03-010
PRE
Allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with t(16;21)(p11;q22)/FUS::ERG
LEUKEMIA
IF13.4
2024-12-100
PRE